National and Kapodistrian University of Athens
Ανακάλυψη νέων μεμβρανικών υποδοχέων και πρωτεϊνών ως φαρμακευτικών στόχων για τη θεραπεία του καρκίνου του μαστού
Abstract
dc:descriptionBreast cancer (BC) is a highly heterogeneous disease encompassing multiple subtypes with different molecular and histopathological features, disease prognosis, and therapeutic responses. Among these, the Triple Negative BC form (TNBC) is an aggressive subtype with poor prognosis and therapeutic outcome. With respect to HER2 overexpressing BC, although advanced targeted therapies have improved the survival of patients, disease relapse and metastasis remains a challenge for therapeutic efficacy. In this study the aim was to identify key membrane-associated proteins which are overexpressed in these aggressive BC subtypes and can serve as potential biomarkers or drug targets. We leveraged on the development of a membrane enrichment protocol in combination with the global profiling GeLC-MS/MS technique, and compared the proteomic profiles of a HER2 overexpressing (HCC-1954) and a TNBC (MDA-MB-231) cell line with that of a benign control breast cell line (MCF-10A). An average of 2300 proteins were identified from each cell line, of which approximately 600 were membrane-associated proteins. Our global proteomic methodology in tandem with invigoration by Western blot and Immunofluorescence analysis, readily detected several previously-established BC receptors like HER2 and EPHA2, but importantly STEAP4 and CD97 emerged as novel potential candidate markers. This is the first time that the mitochondrial iron reductase STEAP4 protein up-regulation is linked to BC (HER2+ subtype), while for CD97, its role in BC has been previously described, but never before by a global proteomic technology in TNBC. STEAP4 was selected for further detailed evaluation by the employment of Immunohistochemical analysis of BC xenografts and clinical tissue microarray studies. Results showed that STEAP4 expression was evident only in malignant breast tissues whereas all the benign breast cases had no detectable levels. A functional role of STEAP4 intervention was established in HER2 overexpressing BC by pharmacological studies, where blockage of the STEAP4 pathway with an iron chelator (Deferiprone) in combination with the HER2 inhibitor Lapatinib led to a significant reduction in cell growth in vitro. Furthermore, siRNA mediated knockdown of STEAP4 also suppressed cell proliferation and enhanced the inhibition of Lapatinib in HER2 overexpressing BC, confirming its potential oncogenic role in BC. In conclusion, STEAP4 may represent a novel BC related biomarker and a potential pharmacological target for the treatment of HER2 overexpressing BC.Complementary approaches for the detection and quantification of well-known receptor targets associated with BC that cannot be readily detected in the discovery phase, such as GPCRs, were based on LC-MRM and LC-PRM methods. GPCRs play a central role in cell signaling and their implication in a variety of human cancers, makes them attractive targets for patient stratification and targeted therapies. In our effort to quantify low abundance GPCRs whose detection by antibody-based assays is challenging we have developed and applied Targeted LC-MS/MS-based approaches, such as Multiple Reaction Monitoring (MRM) and Parallel reaction monitoring (PRM), using representative BC and CaP cell lines. As a paradigm target we chose the Gonadotropin Releasing Hormone Receptor (GnRHR), an established therapeutic target for cancer therapy known to be overexpressed in BC and CaP. Our strategy for the quantification of GnRHR in cancer cells was based on the detection and measurement of the expression levels of synthetic proteotypic peptides. We managed to develop and validate an LC-MRM method for the detection and quantification of the mixture of the reference synthetic peptides of GnRHR, with the use of a Triple Quadrupole MS system. In order to further improve the sensitivity and the reproducibility of our methodology, we proceeded to the LC-PRM technique with the use of a high-resolution Q Exactive Hybrid Quadrupole-Orbitrap MS. The LC-PRM method using a high-resolution MS system goes beyond LC-MRM in that it covers a wider dynamic concentration range with higher mass accuracy (ppm- to sub-ppm levels) and it can monitor all precursor to product transitions. As a result, the LC-PRM technique reduces the number of co-eluting peaks which generate interferences and leads to better sensitivity and reproducibility. Finally, by developing these methodologies we succeeded to determine accurately GnRHR expression levels in specific BC and CaP cell lines (MDA-MB-231, HCC-1954, MCF-7, WPE-NB26-3 και DU-145). In conclusion, our Targeted LC-MRM and LC-PRM strategies are anticipated to be of great importance in clinical practice since we could assess and monitor the expression levels of key receptor targets in cancer cells that could enable efficient and targeted pharmacologic interventions for cancer patients. The targeted proteomics approach can be applied to additional proteins of clinical importance that cannot be detected with antibody-based assays.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Orfanou, Ioanna-Maria
- Ορφανού, Ιωάννα-Μαρία
Subjects
dc:subject × 22- Καρκίνος του μαστού
- Νέοι φαρμακευτικοί στόχοι
- Μεμβρανικές πρωτεϊνες
- GeLC-MS/MS Πρωτεομική τεχνική
- STEAP4
- HER2+ καρκίνος του μαστού
- Συγχορήγηση φαρμάκων
- Στοχευμένες LC-MRM και LC-PRM τεχνικές
- GnRHR
- Breast cancer
- Νovel pharmacological targets
- Μembrane proteins
- GeLC-MS/MS proteomics
- HER2+ breast cancer
- Co-administration schemes
- Targeted LC-MRM and LC-PRM techniques
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ανακάλυψη και Ανάπτυξη φαρμάκων
- Basic Medicine
- Medical and Health Sciences
- Drug Discovery
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/49587